Why UK CBD businesses are declined for banking
The core problem is the gap between the UK's legal framework for CBD and a bank's internal risk assessment. While your CBD products are legal, they originate from the cannabis plant. For a bank's compliance department, this immediately triggers alarms related to the Misuse of Drugs Act 1971 and international anti-money laundering (AML) regulations. Even with a Novel Foods authorisation, banks see ambiguity.
Fintechs like Wise and Revolut, and processors like Stripe, rely on automated, scalable onboarding. Their compliance systems are built to flag and reject entire categories deemed high-risk. A CBD business, regardless of its legitimacy, gets caught in this dragnet. They do not have the manual resources or specialist knowledge to perform the deep due diligence required. For them, it is simply more cost-effective to decline the entire sector than to assess individual businesses. Mainstream banks like HSBC or Barclays follow a similar logic, driven by immense regulatory overhead and a conservative interpretation of their duties. The potential revenue from your account is negligible compared to the perceived risk of regulatory fines or reputational damage.